12:00 AM
 | 
Jan 31, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Peptide Therapeutics preclinical data

PTE said that it has constructed a chimeric vaccine against all four serotypes of dengue virus and that the tetravalent vaccine was safe, induced high levels of...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >